Adectris: Pfizer medication achieves positive results in advanced-stage blood cancer study

Pfizer announced that a combined treatment involving its medication, Adcetris, has achieved the primary objective in a late-stage study aimed at prolonging survival among patients with a specific form of blood cancer.

The safety and tolerability of ADCETRIS in the ECHELON-3 trial were in line with previous findings observed in clinical trials involving patients with relapsed/refractory DLBCL treated with ADCETRIS. Comprehensive data will be presented at an upcoming medical conference.

Roger Dansey, M.D., Pfizer’s Chief Development Officer for Oncology, expressed optimism about the results, noting that this marks the third Phase 3 trial in a lymphoma subtype to show a survival benefit with an ADCETRIS combination. He highlighted the significance of these findings for patients with relapsed or refractory DLBCL, regardless of CD30 expression, particularly given that the study included heavily treated individuals, some of whom had received CAR-T therapy in the past.

DLBCL stands as the most prevalent type of lymphoma, characterized by its rapid growth and aggressive nature. Around 40% of DLBCL patients either fail to respond to initial treatment or experience disease relapse following first-line therapy.

ADCETRIS is an antibody-drug conjugate (ADC) composed of a monoclonal antibody directed at CD30, linked to a microtubule-disrupting agent, monomethyl auristatin E (MMAE), via a protease-cleavable linker, utilizing Seagen’s proprietary technology. The ADC utilizes a linker system engineered to remain stable in the bloodstream but to release MMAE upon internalization into CD30-positive tumor cells.